Angina pectoris stable

Posicor Jun-97 Jun-98 Hypertension and chronic stable angina pectoris 41 million... [Pg.92]

In a placebo controlled, double-blind, multicenter study with 47 chronic stable angina pectoris patients Pirsidomine showed significant hypotensive, anti-ischemic and antianginal effects [126]. [Pg.162]

Stable angina pectoris Decreased myocardial oxygen consumption -decreased LV end-diastolic dimension -decreased LV filling pressure -decreased LV systolic pressure -decreased PVR Increased coronary blood flow -epicardial coronary artery dilation -stenotic segment dilation -coronary collateral vessel dilation -increased subendocardial perfusion... [Pg.289]

Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000 86 1057-1062. [Pg.202]

It is used for arterial hypertension, chronic, stable angina pectoris, preventing angina pectoris, and for ischemic-type abnormalities of brain blood flow. Synonyms of this drug are nerdipina, carden, and others. [Pg.265]

Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris outcomes for patients with double-vessel versus single—vessel coronary artery disease in a Vererans Affairs cooperative randomized trial. J Am Coll Cardiol 1997 29 1505. [Pg.81]

Maseri A. Medical therapy of chronic stable angina pectoris. Circnlation 1990 82 2258-62. [Pg.345]

Parker JD and Parker JO. Drug therapy Nitrate therapy for stable angina pectoris. N Engl J Med... [Pg.205]

Chronic, stable angina pectoris PO Initially, lOOmg/dayassingleordivided dose.Increase at weekly (or longer) intervals. Maintenance 100 50 mg/day. PO (Extended-Release) Initially 100 mg/day as single dose. May increase at least at weekly intervals until optimum clinical response achieved. Maximum 200 mg/day. [Pg.796]

Grines, C.L., M.W. Watkins, G. Helmer, W. Penny, J. Brinker, ID. Marmur, A. West, II Rade, P. Marrott, H.K. Hammond, and R.L. Engler, Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 2002.105(11) 1291-7. [Pg.424]

A 58-year-old man with stable angina pectoris started to use latanoprost eye drops and over the next few days his angina worsened and occurred at rest. After 15 days, he had syncope during physical exercise. Angiography showed coronary spasm. [Pg.123]

Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris a meta-analysis. Coron Artery Dis. 2002 13 427-436. [Pg.318]

Kumar S, Hall RJ. Drug treatment of stable angina pectoris in the elderly defining the place of calcium channel antagonists. Drugs Aging. 2003 20 805-815. [Pg.318]

Parmley WW. Optimum treatment of stable angina pectoris. Cardiovasc Drugs Ther. 1998 12(suppl 1) 105-110. [Pg.318]

S. Savonitto, M. Motolese, and E. Agabiti-Rosei. Antianginal effect of transdermal nitroglycerin and oral nitrates given for 24 hours a day in 2456 patients with stable angina pectoris. Int. J. Clin. Pharmacol. Ther. 33 194—203, 1995. [Pg.37]

Quiles J, Roy D, Gaze D, et al. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 2003 92 322-324. [Pg.10]

One hundred and seventy-three patients (134 males and 39 females), symptomatic patients with stable angina pectoris (Canadian Cardiovascular Society I, 2, 3, or 4) or unstable angina pectoris with documented ischaemia (Braunwald Class IB-C, IIB-C, or IIIB-C) or documented ischemia with a single de novo lesion in a coronary artery suitable for treatment with a single BiodivYsio DD OC-coated coronary stent preloaded with Batimastat of I 1, 15, 18, 22, or 28 mm length by 3.0, 3.5, or4.0-mm diameter were included in the study, providing they met the selection criteria. [Pg.330]

Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002 105(1 I) 1291-1297. [Pg.418]

Betablockers and thiazide diuretics may predispose to ED Mild, stable angina pectoris... [Pg.507]

Increased risk for acute Ml and death ETT may be appropriate, particularly in sedentary patients Moderate, stable angina pectoris ETT may clarify risk Ml >2 wk but <6 wk... [Pg.508]

Sildenafil was the first oral treatment for ED and is the most extensively evaluated (35). Overall success rates in patients with cardiovascular disease of 80% or greater have been recorded with no evidence of tolerance, Patients with diabetes with or without additional risk factors, with their more complex, and extensive pathophysiology, have an average success rate of 60%. In randomized trials to date, open-label or outpatient monitoring studies the use of sildenafil is not associated with any excess risk of myocardial infarction, stroke, or mortality (38-40), In patients with stable angina pectoris there is no evidence of an ischemic effect due to coronary steal, and in one large, double-blind, placebo-controlled, exercise study sildenafil 100 mg increased exercise time and diminished ischemia (41), A study of the hemodynamic effects in men with severe CAD identified no adverse cardiovascular effects and a potentially beneficial effect on coronary blood flow reserve (42), Studies in patients with and without diabetes have demonstrated improved endothelial function acutely and after long-term oral dose administration, which may have implications beyond... [Pg.509]

European Coronary Snrgery Stndy Gronp. Long-term results of prospective randomised stndy of coronary artery bypass surgery in stable angina pectoris. Lancet 1982 2(8309) 1173-80. [Pg.263]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...